文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

经导管主动脉瓣置换术后肾素-血管紧张素系统抑制的获益

Renin-Angiotensin System Inhibition Following Transcatheter Aortic Valve Replacement.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

该多中心研究纳入10家机构2007年8月至2017年8月接受TAVR的2785例重度主动脉瓣狭窄患者,比较出院时是否处方RAS抑制剂。校正基线差异后,RAS抑制剂组左室容积与肥厚逆转更明显,3年心血管死亡更低(OR 0.59;95%CI 0.41–0.87;p=0.007),并见新发房颤、脑血管事件及再入院率更低。

要点

  • TAVR术后出院时使用RAS抑制剂与3年心血管死亡降低相关(OR 0.59)。
  • RAS抑制剂组左室容积缩小与肥厚逆转更明显。
  • 新发房颤、脑血管事件和再入院率在RAS抑制剂组更低。

核心结论

  • TAVR术后使用RAS抑制剂与3年随访心血管死亡降低相关,并具有整体心血管保护作用,部分可能由左室重构改善解释。
  • 作者指出该结果为假设生成性,需正在进行的随机试验RASTAVI(NCT03201185)进一步验证。

研究设计与样本

  • 多中心研究,纳入10家机构2007年8月至2017年8月接受TAVR的重度主动脉瓣狭窄患者。
  • 共纳入2785例,基线数据前瞻性记录并按预定方案随访,按出院时RAS抑制剂处方进行匹配比较。

主要发现

  • RAS抑制剂组(n=1622)外科风险评分相似,但全部心血管危险因素、冠心病及心肌梗死比例更高。
  • 校正基线差异后,RAS抑制剂组左室容积与肥厚逆转更明显,3年心血管死亡更低(OR 0.59;95%CI 0.41–0.87;p=0.007)。
  • RAS抑制剂组新发房颤、脑血管事件及再入院率显著更低。

临床怎么用

  • 对TAVR术后患者,出院时处方RAS抑制剂可能有助于左室重构改善并降低中期心血管事件,但需结合血压、肾功能与血钾个体化评估。
  • 该证据来自观察性匹配分析,不能据此对所有TAVR患者常规强制启用RAS抑制剂,应等待随机试验结果。

局限性

  • 为观察性研究,尽管进行匹配与基线校正,仍可能存在残余混杂。
  • RAS抑制剂剂量与类型仅按出院时记录,未反映随访期间用药变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several studies have demonstrated the benefits of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis, but the presence of persistent fibrosis and myocardial hypertrophy has been related to worse prognosis. OBJECTIVES: The aim of this study was to explore the potential benefits of renin-angiotensin system (RAS) inhibitors on left ventricular remodeling and major clinical outcomes following successful transcatheter aortic valve replacement (TAVR). METHODS: Patients from 10 institutions with severe aortic stenosis who underwent TAVR between August 2007 and August 2017 were included. All baseline data were prospectively recorded, and pre-specified follow-up was performed. Doses and types of RAS inhibitors at discharge were recorded, and matched comparison according to their prescription at discharge was performed. RESULTS: A total of 2,785 patients were included. Patients treated with RAS inhibitors (n = 1,622) presented similar surgical risk scores but a higher rate of all cardiovascular risk factors, coronary disease, and myocardial infarction. After adjustment for these baseline differences, reduction of left ventricular volumes and hypertrophy was greater and cardiovascular mortality at 3-year follow-up was lower (odds ratio: 0.59; 95% confidence interval: 0.41 to 0.87; p = 0.007) in patients treated with RAS inhibitors. Moreover, RAS inhibitors demonstrated a global cardiovascular protective effect with significantly lower rates of new-onset atrial fibrillation, cerebrovascular events, and readmissions. CONCLUSIONS: Post-TAVR RAS inhibitors are associated with lower cardiac mortality at 3-year follow-up and offer a global cardiovascular protective effect that might be partially explained by a positive left ventricular remodeling. An ongoing randomized trial will help confirm these hypothesis-generating findings. (Renin-Angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation [RASTAVI]; NCT03201185).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Rodriguez-Gabella T, Catalá P, Muñoz-García AJ, et al. Renin-Angiotensin System Inhibition Following Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2019. PMID: 31370954. doi:10.1016/j.jacc.2019.05.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。